Rekognan, 1000 mg/4 ml 4 ml 5 pcs

Pharmacological group:

Notropic drug

Pharmacotherapeutic group:

Notropic drug

Pharmacological action

Citicoline, as a precursor of the key ultrastructural components of the cell membrane (mainly phospholipids), has a broad spectrum of action: promotes repair of damaged cell membranes, inhibits the action of phospholipases, preventing excessive formation of free radicals, and also prevents cell death by acting on apoptosis mechanisms.

In the acute period of stroke it reduces the volume of damaged tissue, improves cholinergic transmission.

In brain injury, it reduces the duration of post-traumatic coma and the severity of neurological symptoms, and also helps to reduce the duration of the recovery period.

Cyticoline is effective in the treatment of cognitive, sensory and motor neurological disorders of degenerative and vascular etiology.

In chronic cerebral ischemia, citicoline is effective in the treatment of disorders such as impaired memory, lack of initiative, difficulties in performing daily activities and self-care. It increases the level of attention and consciousness, as well as reduces the manifestation of amnesia.

Pharmacokinetics

Absorption

Cyticolin is well absorbed when taken orally. Absorption after oral administration is almost complete and bioavailability is approximately the same as after IV administration. After oral administration and parenteral administration the plasma concentration of choline is significantly increased.

Distribution

Cyticoline is largely distributed in brain structures, with rapid incorporation of choline fractions into structural phospholipids and citidine fractions into citidine nucleotides and nucleic acids. Cyticoline penetrates the brain and is actively incorporated into cellular, cytoplasmic and mitochondrial membranes, forming part of the structural phospholipids fraction.

Metabolism

In IV and IV/m administration citicoline is metabolized in the liver to form choline and citidine.

Elimination

Only 15% of the administered dose of citicoline is excreted from the human body: less than 3% by the kidneys and intestines and about 12% through the exhaled air.

Two phases can be distinguished in the urinary excretion of citicoline: the first phase, lasting about 36 hours, during which the excretion rate decreases rapidly, and the second phase, during which the excretion rate decreases much more slowly. The same is observed in exhaled air – the excretion rate drops rapidly after about 15 h and then decreases much more slowly.

Indications

Active ingredient

Composition

Associates:

Hydrochloric acid or sodium hydroxide to pH 6.5-7.5,

d/i water – up to 4 ml.

How to take, the dosage

The drug is administered by IV or IM.

In/v is administered as a slow IV injection (over 3-5 minutes, depending on the prescribed dose) or as an IV drip infusion (40-60 drops/minute).

The IV route of administration is preferable to the IV/m route. Repeated administration of the drug to the same site should be avoided when administered by IV.

Acute period of ischemic stroke and traumatic brain injury: 1000 mg every 12 hours from the first day after diagnosis. The duration of treatment is at least 6 weeks. In 3-5 days after the beginning of treatment (if swallowing function is not impaired) conversion to oral forms of Recognan® is possible.

The recovery period of ischemic and hemorrhagic strokes, the recovery period of CHT, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: 500-2000 mg/day. The dose and duration of treatment depend on the severity of the symptoms. Oral forms of Recognan® may be used.

Dose adjustment is not necessary in elderly patients.

The solution in the ampoule is for single use. It should be used immediately after opening the ampoule.

The drug is compatible with all types of isotonic infusion solutions and dextrose solutions.

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Similarities